Skip to main content
    O

    Ovid Therapeutics Inc (OVID)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $2.22
    -0.18 (-7.50%)

    Market Cap: $479.38M

    Last updated: Nov 17, 2026 at 4:33 PM ET

    Ovid Therapeutics Inc (OVID) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Ovid Therapeutics (OVID) has a market cap of $479.38M and an enterprise value of $465.57M. It kept -2971.33% of revenue as net income over the last 12 months. Its share count is up 185.48% from a year earlier.

    Total Valuation

    Enterprise value is 2.88% below the market cap, as cash exceeds debt.

    Market Cap$479.38M
    Enterprise Value$465.57M
    Latest price (Nov 17, 2026)$2.22

    Key Dates

    The next earnings report is expected on Mar 16, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateMar 16, 2027 (expected)
    Last Earnings DateNov 10, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 2.82% in the quarter ended Sep 30, 2026 and grew 69.13% a year over 2 years.

    Shares Outstanding203.02M
    Shares Change (YoY)+185.48%
    Shares Change (QoQ)+2.82%
    Share Count Growth (2Y CAGR)+69.13%

    Valuation Ratios

    Sales and book value multiples are 310.6x and 2.3x. Its year-end P/S ranged from 11.2x to 580.0x from 2020 to 2025.

    P/S Ratio310.6x
    Forward P/S591.5x
    P/B Ratio2.3x
    P/TBV Ratio2.9x

    Valuation history and multiples

    Price Statistics

    The stock is up 70.11% over 52 weeks and trades 10.84% below its 50-day average.

    Beta (1Y)1.46
    52-Week Change+70.11%
    1-Month Change+2.30%
    3-Month Change-24.23%
    6-Month Change-7.50%
    5-Year Change-25.29%
    Total Return (1Y)+70.11%
    Total Return (3Y CAGR)-12.11%
    Total Return (5Y CAGR)-8.01%
    Return vs SPY (1Y)+56.62%
    Max Drawdown (1Y)-27.36%
    Max Drawdown (3Y)-93.69%
    Sharpe Ratio (1Y)0.68
    Correlation with SPY (1Y)0.26
    50-Day Average$2.49
    200-Day Average$2.42
    52-Week Range$1.21 to $3.10
    RSI (14 Days)40.1
    Average Volume (20 Days)2.63M

    The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 11.97x current liabilities, and total debt is 0.00x shareholder equity.

    Current Ratio11.97x
    Quick Ratio11.97x
    Debt / Equity0.00x

    Returns and Efficiency

    Return on equity is -21.70% over the last 12 months, against a 5-year average of -16.86%.

    Return on Equity (ROE)-21.70%
    Return on Assets (ROA)-19.40%
    Return on Capital Employed (ROCE)-20.49%
    ROE (5Y Average)-16.86%
    ROA (5Y Average)-9.66%
    ROIC (5Y Average)-10.53%
    Asset Turnover0.01x

    Scores

    OVID has an Altman Z-Score of 9.18, in the safe zone above 2.99, and a Piotroski F-Score of 3 of 9, in the average band of 3 to 7.

    Altman Z-Score9.18
    Altman Z ZoneSafe
    Piotroski F-Score3 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue of $1.45M over the last 12 months is down 78.05% from the 12 months before.

    Revenue$1.45M
    Revenue Growth (YoY)-78.05%
    Gross Profit$1.45M
    Operating Income-$68.20M
    Pretax Income-$43.11M
    Net Income-$43.11M
    EBITDA-$41.77M
    EBIT-$43.11M
    Reported EPS (TTM)-$0.24

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 89.39% of the $222.24M in total assets.

    Cash and Equivalents$13.81M
    Total Debt$0
    Net Cash$13.81M
    Net Cash Per Share$0.07
    Working Capital$130.10M
    Shareholder Equity$198.67M
    Book Value Per Share$0.98
    Tangible Book Value$155.98M
    Tangible Book Per Share$0.77
    Total Assets$222.24M
    Total Liabilities$23.57M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    Operating Cash Flow-$57.78M
    FCF Per Share-$0.30
    Depreciation and Amortization$1.34M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is -4700.28%.

    Gross Margin100.00%
    Operating Margin-4700.28%
    Pretax Margin-2971.33%
    Net Margin-2971.33%
    EBITDA Margin-2878.77%
    EBIT Margin-2971.26%

    Growth

    Revenue grew 68.99% a year over 3 years.

    Revenue Growth (3Y CAGR)+68.99%
    Revenue Growth (5Y CAGR)-10.48%
    Book Value Per Share Growth (2Y CAGR)+13.49%
    Tangible Book Per Share Growth (2Y CAGR)-6.49%

    Revenue and profit by year

    Dividends and Yields

    OVID does not pay a dividend.

    Buyback Yield-14.79%
    Shareholder Yield-14.79%

    Peer Position

    Against 4 similar companies, OVID has the highest P/S.

    P/S Ratio310.6x vs 27.9x median
    Revenue Growth (Trailing 4 Quarters, YoY)-78.05% vs -83.94% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at -81.12% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)-81.12%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Frequently Asked Questions About OVID

    What is OVID's market cap?

    Ovid Therapeutics has a market cap of $479.38M. Its enterprise value, which adds debt and subtracts cash, is $465.57M.

    How many shares of OVID are outstanding?

    Ovid Therapeutics has 203.02M shares outstanding. The count is up 185.48% from a year earlier.

    Does OVID pay a dividend?

    No. Ovid Therapeutics does not pay a dividend.

    How much debt does OVID have?

    Ovid Therapeutics has $0 of total debt and $13.81M of cash and equivalents, a net cash position of $13.81M.